These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 6533925

  • 1. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C, Poignet JL, Mauras Y, Panthier G, Delons S, Allain P, Man NK.
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract] [Full Text] [Related]

  • 2. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M, Popławski A, Kaliszewski Z, Juzwiuk J.
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [Abstract] [Full Text] [Related]

  • 3. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
    Poignet JL, Monge MF, Ciancioni C, Mikol F, Naret C, Delons S, Man NK.
    Trans Am Soc Artif Intern Organs; 1985 Oct; 31():546-51. PubMed ID: 3837504
    [No Abstract] [Full Text] [Related]

  • 4. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H, Stummvoll HK, Meisinger V.
    Proc Eur Dial Transplant Assoc; 1981 Oct; 18():674-80. PubMed ID: 7329995
    [Abstract] [Full Text] [Related]

  • 5. Prevention and treatment of aluminum intoxication in chronic renal failure.
    Simon P, Allain P, Ang KS, Cam G, Mauras Y.
    Adv Nephrol Necker Hosp; 1985 Oct; 14():439-78. PubMed ID: 3919543
    [No Abstract] [Full Text] [Related]

  • 6. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM, van de Vyver FL, D'Haese PC, van Acker KJ, Visser WJ, de Broe ME.
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure.
    Malluche HH, Smith AJ, Abreo K, Faugere MC.
    N Engl J Med; 1984 Jul 19; 311(3):140-4. PubMed ID: 6377067
    [Abstract] [Full Text] [Related]

  • 9. Effect of desferrioxamine on aluminum kinetics during hemodialysis.
    Stummvoll HK, Graf H, Meisinger V.
    Miner Electrolyte Metab; 1984 Jul 19; 10(4):263-6. PubMed ID: 6749073
    [Abstract] [Full Text] [Related]

  • 10. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
    Simon P.
    Nephrologie; 1986 Jul 19; 7(5):177-80. PubMed ID: 3822038
    [No Abstract] [Full Text] [Related]

  • 11. Aluminum kinetics of the REDY system: a study of the impact of deferoxamine therapy.
    Culpepper CP, Cummings R, Westervelt FB, Savory J, Wills MR.
    Trans Am Soc Artif Intern Organs; 1983 Jul 19; 29():76-80. PubMed ID: 6673321
    [No Abstract] [Full Text] [Related]

  • 12. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS, Hercz G, Miller JH, Shinaberger JH, Nissenson AR, Coburn JW.
    Kidney Int Suppl; 1986 Feb 19; 18():S100-3. PubMed ID: 3457984
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis.
    Allain P, Chaleil D, Mauras Y, Beaudeau G, Varin MC, Poignet JL, Ciancioni C, Ang KS, Cam G, Simon P.
    Clin Chim Acta; 1987 Dec 19; 170(2-3):331-8. PubMed ID: 3436066
    [Abstract] [Full Text] [Related]

  • 14. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P, Ralston AJ, Day JP.
    Kidney Int Suppl; 1986 Feb 19; 18():S104-7. PubMed ID: 3457985
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients.
    Klemm A, Sperschneider H, Winnefeld K, Günther K, Stein G.
    Clin Nephrol; 1997 Feb 19; 47(2):133-4. PubMed ID: 9049466
    [No Abstract] [Full Text] [Related]

  • 16. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
    Bournerias F, Monnier N, Dufier JL, Réveillaud RJ.
    Nephrologie; 1987 Feb 19; 8(1):27-9. PubMed ID: 3587485
    [Abstract] [Full Text] [Related]

  • 17. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM, Corwin HL, Wilson RS, Mayor GH, Tanner CM.
    Arch Intern Med; 1986 Oct 19; 146(10):2063-4. PubMed ID: 3767553
    [Abstract] [Full Text] [Related]

  • 18. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P, Bonn F, Guezennec M, Tanquerel T, Ksang.
    Nephrologie; 1981 Oct 19; 2(4):165-70. PubMed ID: 7329501
    [Abstract] [Full Text] [Related]

  • 19. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG, Andress DL, Milliner DS, Ott SM, Alfrey AC, Slatopolsky EA, Sherrard DJ, Coburn JW.
    Kidney Int Suppl; 1986 Feb 19; 18():S96-9. PubMed ID: 3458006
    [No Abstract] [Full Text] [Related]

  • 20. Changes in bone histology after treatment with desferrioxamine.
    Ott SM, Andress DL, Nebeker HG, Milliner DS, Maloney NA, Coburn JW, Sherrard DJ.
    Kidney Int Suppl; 1986 Feb 19; 18():S108-13. PubMed ID: 3457986
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.